drugset / Trial / NCT01510327
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions are located in vessels that are average-sized.
Timeline
- Start
- 2009-10
- Primary completion
- 2010-02
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Aspirin | Small molecule | 75 mg | — |
| Background | Aspirin | Small molecule | 162 mg | — |
| Background | Clopidogrel | Small molecule | 75 mg | — |
| Background | Prasugrel | Small molecule | — | — |
| Background | ticlopidine | Small molecule | 250 mg | — |